This study examines the effects of the TPP on the Canadian public health care system. It finds that the TPP investor protections would make it more difficult and costly for Canadian governments to establish new public health programs, including pharmacare, which is on the agenda of ongoing federal-provincial health talks.
The overarching impacts of the proposed treaty would be to weaken the Canadian public health care system, undermine health regulation, and obstruct efforts to renew and expand public health care in the face of new challenges.
Read more reports in our TPP series, What’s the big deal? Understanding the Trans-Pacific Partnership.